Nautilus Biotechnology (NAUT) vs Seer (SEER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Seer (SEER) over the past year, gaining 101.8% versus a loss of 3.6%. Over five years, NAUT leads with a -68.1% price change compared with -93.4% for SEER. Nautilus Biotechnology is the larger company by market cap ($231.6 million vs $120.2 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAUT | SEER |
|---|---|---|
| Share price | $1.82 | $2.17 |
| Market cap | $231.60M | $120.16M |
| 1-day change | -7.14% | -1.81% |
| YTD return | -6.67% | +18.58% |
| 1-year return | +101.77% | -3.56% |
| 5-year return | -68.13% | -93.42% |
| EPS (TTM) | $-0.45 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.31 | $2.41 |
| 52-week low | $0.82 | $1.55 |
| Distance from 52-week high | -57.77% | -9.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +110.44% | +84.33% |
| Average volume | 2.66M | 479.14K |
| Shares outstanding | 127.26M | 55.37M |
| Employees | 127 | 124 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NAUT has outperformed SEER by 105.3 percentage points over the past year.
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
About Seer
SEER stock →Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Industrials · Biotechnology: Laboratory Analytical Instruments · 124 employees
NAUT vs SEER FAQ
Which is bigger, Nautilus Biotechnology or Seer?
Nautilus Biotechnology (NAUT) is larger, with a market capitalization of $231.60M compared with $120.16M for Seer (SEER).
Which stock has performed better over the past year, NAUT or SEER?
NAUT returned +101.77% over the past 12 months, compared with -3.56% for SEER (price return, excluding dividends). Past performance does not predict future results.
Are Nautilus Biotechnology and Seer in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.